Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Low-Level Laser Therapy Efficacy in Pain Management of Grade 2 Oral Mucositis Induced by Radiotherapy or Chemoradiotherapy: a Study in Patients With Upper Aerodigestive Tract Cancer (ESMULLLAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03955224
Recruitment Status : Withdrawn (Withdrawn due to lack of recruitment)
First Posted : May 20, 2019
Last Update Posted : April 8, 2021
Sponsor:
Information provided by (Responsible Party):
Institut Claudius Regaud

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Prospective, monocentric, randomized phase II study evaluating Low-Level Laser Therapy (LLLT) as a treatment for the pain due to grade 2 oral mucositis in patients with upper aero-digestive tract cancer treated by radiotherapy or chemoradiotherapy.

Patients with upper aero-digestive tract cancer receiving their first cervicofacial radiotherapy or chemoradiotherapy will be included in this study if they suffer from oral mucositis due to their treatment.

The study procedure will consist in 5 applications of the LLLT that will be performed at three days intervals for a maximum duration of 15 days.

Each patient will be followed until 3 days after the end of the study treatment, for a total duration of the study of 18 days.


Condition or disease Intervention/treatment Phase
Upper Aerodigestive Tract Neoplasms Device: Basic Oral Care + active LLLT Other: Basic oral Care + inactive LLLT Other: Basic Oral Care Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Evaluation of Low-Level Laser Therapy Efficacy in Pain Management of Grade 2 Oral Mucositis Induced by Radiotherapy or Chemoradiotherapy: a Phase II Randomized Study in Patients With Upper Aerodigestive Tract Cancer
Estimated Study Start Date : March 2021
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : October 2022

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Basic Oral Care + active LLLT (experimental arm) Device: Basic Oral Care + active LLLT
  • Compliance with the Basic Oral Care Associated with
  • Active LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)
Placebo Comparator: Basic oral Care + inactive LLLT (control arm) Other: Basic oral Care + inactive LLLT
  • Compliance with the Basic Oral Care Associated with
  • Inactive LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)
Basic Oral Care (control arm) Other: Basic Oral Care
Compliance with the Basic Oral Care only


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Rate of patients who didn't need a dose increase or introduction of new analgesics for mouth pain during the study compared to baseline [ Time Frame: 16 days for each patient ]

Secondary Outcome Measures :
  1. Evaluation of the oral mucositis pain intensity with Visual Analog Scale Scores [ Time Frame: 16 days for each patient ]
  2. Quality of Life assessed by the Quality of Life Questionnaire specific to Head and Neck cancer (H&N35) [ Time Frame: 16 days for each patient ]
  3. Frequency of adverse events related to the LLLT using the National Cancer Institute Common Toxicity Criteria for Adverse Effects (NCI CTCAE) version 5.0 [ Time Frame: 16 days for each patient ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Patients with upper aero-digestive tract cancer receiving a first cervicofacial radiotherapy or chemoradiotherapy
  3. Patients with a grade 2 mucositis (according to the NCI CTCAE version 5.0) appearing during treatment.
  4. Patients available to perform the LLLT treatment: 5 visits at 3 days intervals
  5. Patients must provide written informed consent prior to any study specific procedures.
  6. Patients affiliated to a Social Health Insurance in France.

Exclusion Criteria:

  1. Patients who have already received a cervicofacial radiotherapy
  2. Patients who have already received an induction chemotherapy for their upper aero-digestive tract cancer
  3. Patients under targeted therapy for their upper aero-digestive tract cancer
  4. Patients under systemic corticotherapy
  5. Patients with a non-grade 2 mucositis (according to the NCI CTCAE version 5.0)
  6. Patients with ulceration or any other oral mucosa pathology than mucositis
  7. Pregnant or breastfeeding women
  8. Any psychological, familial, geographical or sociological condition which does not allow to respect the medical follow-up and/or compliance to study procedure
  9. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03955224


Locations
Layout table for location information
France
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, France
Sponsors and Collaborators
Institut Claudius Regaud
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Institut Claudius Regaud
ClinicalTrials.gov Identifier: NCT03955224    
Other Study ID Numbers: 19 VADS 04
First Posted: May 20, 2019    Key Record Dates
Last Update Posted: April 8, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Institut Claudius Regaud:
Upper Aerodigestive Tract Neoplasms
Low-Level Laser Therapy (LLLT)
Mucositis
Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Mucositis
Stomatitis
Neoplasms
Gastroenteritis
 Gastrointestinal Diseases
Digestive System Diseases
Mouth Diseases
Stomatognathic Diseases
Neoplasms by Site